I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Dual antiplatelet therapy (DAPT) mitigates the risk of stent thrombosis (ST) and ischemic events in patients who undergo percutaneous coronary intervention (PCI).\[[@ref1]\] Nonetheless, antiplatelet therapy is also associated with increased bleeding risk, and gastrointestinal bleeding accounts for a notable proportion of the bleeding complications of DAPT and probably leads to DAPT cessation, which further increases adverse cardiovascular events.\[[@ref2]\] Proton-pump inhibitors (PPIs) are often concomitantly prescribed to patients in combination with DAPT to help reduce the occurrence of gastrointestinal bleeding.\[[@ref3]\] However, several pharmacokinetic studies and observational studies have demonstrated potential interaction of PPIs with clopidogrel via competition with liver cytochrome P450 isoenzymes (especially CYP2C19), leading to reduced antiplatelet activity and increased ischemic events.\[[@ref2][@ref4][@ref5][@ref6][@ref7][@ref8]\] New evidences showed that the interaction may have no clinical significance.\[[@ref9][@ref10]\] Limited by the controversial conclusions, the 2016 American College of Cardiology/American Heart Association guideline on DAPT in patients with coronary artery disease suggested no routine PPI use in the setting of DAPT.\[[@ref11]\] However, the 2017 European Society of Cardiology focused update on DAPT in coronary artery disease recommended PPI in combination with DAPT.\[[@ref1]\] Therefore, we performed a large prospective observational study to evaluate the interaction between PPIs and DAPT among high-risk cardiovascular patients who underwent PCI from both pharmacodynamic and clinical aspects. Propensity score matching (PSM) was implemented to eliminate the covariate imbalance.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

The study was conducted in accordance with the *Declaration of Helsinki* and was approved by the Fuwai Hospital Institutional Ethical Review Board. Informed written consent was obtained from all patients or their guardians, in the case of children, prior to their enrollment in this study.

Study population {#sec2-2}
----------------

All 10,724 consecutive patients from a single center (Fu Wai Hospital, National Center for Cardiovascular Diseases, Beijing, China) who underwent PCI throughout 2013 were enrolled in the study. Of these, 21 patients were prescribed aspirin and ticagrelor, and two patients were prescribed oral anticoagulant after PCI. Ticagrelor is a P2Y12 inhibitor that does not need biotransformation and has no effect on the CYP2C19 isoenzyme. Thus, only patients treated with aspirin and clopidogrel were included (*n* = 10,701). Patients with missing values of PPI use and loss of follow-up were excluded \[*n* = 2833, [Figure 1](#F1){ref-type="fig"}\].

![Patient flowchart for the study cohort. PCI: Percutaneous coronary intervention; DAPT: Dual antiplatelet therapy; OAC: Oral anticoagulants; PPI: Proton-pump inhibitors; mTEG: Modified thromboelastograph.](CMJ-130-2899-g001){#F1}

Procedure and medications {#sec2-3}
-------------------------

The PCI strategy and stent type were determined by the physician\'s discretion. Before the procedure, all patients who had not taken long-term aspirin and P2Y12 inhibitors received oral 300 mg aspirin and 300 mg clopidogrel. After the procedure, patients were to take aspirin 100 mg/d indefinitely and clopidogrel 75 mg/d for at least 1 year after PCI. PPI use was determined at the physician\'s discretion and was recorded at the time of PCI. The specific PPI was not reported.

Data collection and study endpoints {#sec2-4}
-----------------------------------

Baseline clinical characteristics, past medical history, laboratory tests, PCI data, and discharge medications were collected. All patients were evaluated at a clinic visit or by phone at 1, 6, 12, and 24 months. The average follow-up was 875.3 days. The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE) during follow-up. MACCE were defined as a composite of all-cause death, myocardial infarction (MI), unplanned target vessel revascularization (TVR), ST, and stroke. MI was defined according to the clinical and laboratory parameters established in the third universal definition of MI.\[[@ref12]\] Unplanned TVR was defined as any repeat PCI or surgical bypass of any segment of the target vessel for ischemic symptoms and events. ST was defined by the Academic Research Consortium, and definite and probable ST were included in the analysis.\[[@ref13]\] Secondary endpoints included each component of the primary endpoint. Bleeding was quantified according to the Bleeding Academic Research Consortium Definition (BARC) criteria, and types 2, 3, and 5 were included in the analysis.\[[@ref14]\] Major bleeding was defined as type 3 and 5 according to the BARC criteria. All endpoints were adjudicated centrally by two independent cardiologists, and disagreement was resolved by consensus.

Blood sampling {#sec2-5}
--------------

According to the physician\'s discretion, platelet aggregation inhibition tests were performed by modified thromboelastography (mTEG, Haemonetics Corp., Massachusetts, USA). Blood was collected at least 6 h after using clopidogrel in a Vacutainer tube containing 3.2% trisodium citrate. The Vacutainer tube was filled to capacity and inverted 3--5 times to ensure complete mixing of the anticoagulant. The mTEG instrument uses 4 channels to detect the effects of antiplatelet therapy acting via the arachidonic acid and adenosine diphosphate (ADP) pathways.\[[@ref15]\] An mTEG hemostasis analyzer (Haemonetics Corp., Massachusetts, USA) and automated analytical software (Haemonetics Corp., Massachusetts, USA) were used to measure the physical properties. ADP inhibition % of \<30% was considered a clopidogrel low response (CLR).\[[@ref16]\]

Statistical analysis {#sec2-6}
--------------------

Categorical variables are presented as numbers (percentages) and were compared using the Chi-squared test. Continuous variables are presented as the means ± standard deviation or median (interquartile range) and were compared using the *t*-test or Mann-Whitney *U*-test. Hazard ratios (*HR*s) are presented with the 95% confidence intervals (*CI*s). All statistical analyses were performed using SPSS version 23.0 (SPSS Inc., Chicago, IL, USA), and a two-tailed *P* \< 0.05 was considered statistically significant. Kaplan-Meier analysis was applied to evaluate endpoints. The covariates for Cox proportional regression were those variables with significant differences at baseline or important clinical meaning.

To minimize the effect of confounding factors caused by differences in baseline characteristics between patients with and without PPI use, PSM was performed for both the whole population and the mTEG population. A propensity score was estimated for each patient using a logistic regression model. Patients were matched on estimated propensity scores, with replacement, using a nearest neighbor approach. A caliper width of 0.02 was used. For the total population, the dependent variable was PPI use, and the covariates were age, gender, hypertension, dyslipidemia, diabetes mellitus, prior cerebrovascular disease, prior MI, prior PCI, prior coronary artery bypass grafting, acute MI, ejection fraction, Killip class, estimated glomerular filtration rate, hemoglobin, intra-aortic balloon pump, and warfarin use. For the mTEG population, the dependent variable was PPI use, and the covariates were age, gender, prior cerebrovascular disease, prior MI, prior PCI, acute MI, ejection fraction, estimated glomerular filtration rate, hemoglobin, and intra-aortic balloon pump.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Study population and demographics {#sec2-7}
---------------------------------

Among 7868 enrolled patients, 2142 (27.2%) patients were prescribed PPIs. PPI users were older and were more likely to be female with a higher rate of cerebrovascular disease and a lower rate of prior MI. These individuals presented more frequently with acute MI and needed more intra-aortic balloon pump support. With respect to laboratory tests, PPI-treated patients had worse heart and renal function, lower hemoglobin levels, and a faster erythrocyte sedimentation rate. PPI users received warfarin more often than non-PPI users. There were significant differences in the baseline levels between the two groups. After PSM, 1966 patients had an estimated propensity score that matched within the 0.02 caliper to 1966 patients without PPI use \[[Table 1](#T1){ref-type="table"}\].

###### 

Baseline characteristics among all patients according to PPI use before and after PSM

  Parameters                   Before PSM             After PSM                                                                                                   
  ---------------------------- ---------------------- ---------------------- ------------- ------------ ---------------------- ---------------------- ----------- ---------
  Demographics                                                                                                                                                    
   Gender (female)             527 (24.6)             1145 (20.0)            19.768\*      \<0.001      485 (24.7)             447 (22.7)             2.031\*     0.154
   Age (years)                 60.2 ± 10.6            57.7 ± 10.3            −9.402^†^     \<0.001      60.2 ± 10.5            60.8 ± 9.9             1.908^†^    0.057
  Past medical history                                                                                                                                            
   Hypertension                1362 (63.6)            3653 (63.8)            0.030\*       0.862        1259 (64.0)            1286 (65.4)            0.812\*     0.368
   Dyslipidemia                1417 (66.2)            3870 (67.6)            1.453\*       0.228        1316 (66.9)            1409 (71.7)            10.340\*    0.001
   Diabetes mellitus           615 (28.7)             1773 (31.0)            3.742\*       0.053        571 (29.0)             595 (30.3)             0.702\*     0.402
   PAD                         66 (3.1)               137 (2.4)              2.941\*       0.086        63 (3.2)               71 (3.6)               0.494\*     0.482
   Prior CVD                   289 (13.5)             570 (10.0)             20.057\*      \<0.001      261 (13.3)             260 (13.2)             0.002\*     0.962
   Prior MI                    430 (20.1)             1586 (27.7)            47.539\*      \<0.001      404 (20.5)             666 (33.9)             88.138\*    \<0.001
   Prior PCI                   591 (27.6)             1653 (28.9)            1.248\*       0.264        500 (25.4)             960 (48.8)             230.530\*   \<0.001
   Prior CABG                  85 (3.9)               276 (4.8)              2.883\*       0.090        81 (4.1)               152 (7.7)              22.998\*    \<0.001
  Admission features                                                                                                                                              
   Acute MI                    598 (27.9)             1224 (21.4)            37.488\*      \<0.001      486 (24.7)             432 (22.0)             4.144\*     0.042
   LVEF, %                     61.5 ± 7.9             62.2 ± 7.6             3.360^†^      0.001        62.0 ± 7.7             61.6 ± 7.9             −1.623^†^   0.105
   Killip class ≥2             45 (2.1)               72 (1.3)               7.570\*       0.006        30 (1.5)               37 (1.9)               0.744\*     0.388
   SAP (mmHg)                  126.1 ± 17.5           126.3 ± 16.8           0.346^†^      0.729        126.3 ± 17.4           126.9 ± 16.5           1.133^†^    0.257
   Current smoking             1247 (58.2)            3384 (59.1)            0.501\*       0.479        1134 (57.7)            1109 (56.4)            0.649\*     0.421
  Laboratory test                                                                                                                                                 
   BNP (pg/ml)                 649.8 (480.3--912.7)   616.6 (474.9--847.3)   −2.879^‡^     0.004        649.3 (479.9--649.3)   640.2 (490.6--895.6)   −0.124^‡^   0.901
   eGFR (ml/min)               88.9 ± 15.9            91.8 ± 15.1            7.209^†^      \<0.001      89.2 ± 15.5            88.6 ± 15.6            −1.203^†^   0.229
   ESR (mm/h)                  7 (3--16)              7 (3--14)              −2.780^‡^     0.005        7 (3--16)              7 (3--14)              −0.383^‡^   0.702
   Hemoglobin (g/L)            141.4 ± 16.0           144.2 ± 15.1           6.970^†^      \<0.001      141.4 ± 16.0           141.4 ± 15.3           0.070^†^    0.944
  Procedural characteristics                                                                                                                                      
   Thrombolysis                85 (4.0)               194 (3.4)              1.534\*       0.215        79 (4.0)               63 (3.2)               1.870\*     0.171
   Syntax score                                                                                                                                                   
    0--22                      1871 (87.3)            5078 (88.7)            2.773\*       0.250        1726 (87.9)            1800 (91.6)            13.953\*    0.001
    23--32                     234 (10.9)             555 (9.7)              206 (10.5)    145 (7.4)                                                              
    ≥33                        37 (1.7)               93 (1.6)               31 (1.6)      21 (1.1)                                                               
   Number of Stents                                                                                                                                               
    0                          137 (6.4)              318 (5.6)              2.082\*       0.353        117 (6.0)              121 (6.2)              6.534\*     0.038
    1                          875 (40.8)             2344 (40.9)            784 (39.9)    859 (43.7)                                                             
    ≥2                         1130 (52.8)            3064 (53.5)            1065 (54.2)   986 (50.2)                                                             
   IABP                        49 (2.3)               74 (1.3)               10.034\*      0.002        32 (1.6)               29 (1.5)               0.150\*     0.699
  Medication                                                                                                                                                      
   Warfarin                    9 (0.4)                8 (0.1)                5.687\*       0.017        4 (0.2)                6 (0.3)                0.401\*     0.527
   GPI                         360 (16.8)             936 (16.3)             0.240\*       0.624        322 (16.4)             336 (17.1)             0.358\*     0.550

Data are presented as *n* (%), mean ± SD or median (interquartile range). \**χ*^2^ values; ^†^*t* values; ^‡^*z* value. PPI: Proton-pump inhibitors; PSM: Propensity score matching; PAD: Peripheral artery disease; CVD: Cerebrovascular disease; MI: Myocardial infarction; PCI: Percutaneous coronary intervention; CABG: Coronary artery bypass grafting; LVEF: Left ventricular ejection fraction; SAP: Systolic blood pressure; BNP: Brain natriuretic peptide; eGFR: Estimated glomerular filtration rate; ESR: Erythrocyte sedimentation rate; IABP: Intra-aortic balloon pump; GPI: Glycoprotein IIb/IIIa inhibitors; SD: Standard deviation.

Adenosine diphosphate-induced platelet aggregation inhibition test {#sec2-8}
------------------------------------------------------------------

ADP-induced platelet aggregation inhibition was measured by mTEG in 5042 patients per the physician\'s discretion. The baseline characteristics of patients were compared according to PPI use in the mTEG population, and the two groups were better matched after PSM with 1297 patients selected from each group \[[Table 2](#T2){ref-type="table"}\].

###### 

Baseline characteristics among patients receiving mTEG according to PPI use before and after PSM

  Parameters                   Before PSM             After PSM                                                                                                   
  ---------------------------- ---------------------- ---------------------- ------------ ------------ ---------------------- ---------------------- ------------ ---------
  Demographics                                                                                                                                                    
   Gender (female)             341 (24.9)             721 (19.6)             16.857\*     \<0.001      324 (25.0)             260 (20.0)             9.052\*      0.003
   Age (years)                 59.9 ± 10.5            57.6 ± 10.3            −7.145^†^    \<0.001      59.9 ± 10.6            59.1 ± 10.5            −2.0368^†^   0.042
  Past medical history                                                                                                                                            
   Hypertension                890 (65.1)             2343 (63.8)            0.746\*      0.388        849 (65.5)             854 (65.8)             0.043\*      0.839
   Dyslipidemia                916 (67.0)             2507 (68.2)            1.453\*      0.228        869 (67.0)             879 (67.8)             0.175\*      0.675
   Diabetes mellitus           409 (29.9)             1124 (30.6)            0.228\*      0.633        394 (30.4)             388 (29.9)             0.066\*      0.797
   PAD                         48 (3.5)               94 (2.6)               3.289\*      0.070        46 (3.5)               37 (2.9)               1.008\*      0.315
   Prior CVD                   187 (13.7)             342 (9.3)              20.187\*     \<0.001      175 (13.5)             179 (138)              0.052\*      0.819
   Prior MI                    279 (20.4)             1035 (28.2)            31.282\*     \<0.001      263 (20.3)             277 (21.4)             0.458\*      0.498
   Prior PCI                   352 (25.7)             1062 (28.9)            4.979\*      0.026        317 (24.4)             335 (25.8)             0.664\*      0.415
   Prior CABG                  63 (4.6)               171 (4.7)              0.005\*      0.941        61 (4.7)               62 (4.8)               0.009\*      0.926
  Admission features                                                                                                                                              
   Acute MI                    300 (21.9)             698 (19.0)             5.396\*      0.020        267 (20.6)             228 (17.6)             3.797\*      0.051
   LVEF (%)                    62.0 ± 7.8             62.4 ± 7.5             1.607^†^     0.108        62.2 ± 7.6             62.4 ± 7.5             0.587^†^     0.557
   Killip class ≥2             19 (1.4)               30 (0.8)               3.393\*      0.065        15 (1.2)               14 (1.1)               0.035\*      0.852
   SAP (mmHg)                  126.2 ± 17.3           126.5 ± 16.7           0.641^†^     0.522        126.3 ± 17.3           127.3 ± 16.9           1.564^†^     0.118
   Current smoking             783 (57.2)             2151 (58.5)            0.703\*      0.402        738 (56.9)             749 (57.7)             0.191\*      0.662
  Laboratory test                                                                                                                                                 
   BNP (pg/ml)                 648.8 (474.6--909.2)   615.7 (480.5--843.6)   −2.030^‡^    0.042        646.4 (474.1--911.6)   610.6 (480.6--842.5)   −1.832^‡^    0.067
   eGFR (ml/min)               89.6 ± 15.4            92.2 ± 14.7            5.408^†^     \<0.001      89.6 ± 15.4            90.4 ± 15.1            1.354^†^     0.176
   ESR (mm/h)                  7 (4--16)              7 (3--14)              −2.983^‡^    0.003        7 (4--16)              7 (3--13)              −3.795^‡^    \<0.001
   Hemoglobin (g/L)            140.9 ± 15.9           144.2 ± 14.8           6.553^†^     \<0.001      140.9 ± 15.9           144.3 ± 16.0           5.472^†^     \<0.001
  Procedural characteristics                                                                                                                                      
   Thrombolysis                50 (3.7)               134 (3.6)              \<0.001\*    0.990        49 (3.8)               50 (3.9)               0.011\*      0.918
   Syntax score                                                                                                                                                   
    0--22                      1188 (86.8)            3233 (88.0)            1.615\*      0.446        1129 (87.0)            1143 (88.1)            0.796\*      0.672
    23--32                     153 (11.2)             383 (10.4)             143 (11.0)   133 (10.3)                                                              
    ≥33                        27 (2.0)               58 (1.6)               25 (1.9)     21 (1.6)                                                                
  Number of stents                                                                                                                                                
    0                          80 (5.8)               207 (5.6)              1.055\*      0.590        72 (5.6)               66 (5.1)               0.279\*      0.870
    1                          512 (37.48)            1433 (39.0)            485 (37.4)   486 (37.5)                                                              
    ≥2                         776 (56.7)             2034 (55.4)            740 (57.1)   745 (57.4)                                                              
   IABP                        29 (2.1)               36 (1.0)               10.181\*     0.001        21 (1.6)               19 (1.5)               0.102\*      0.750
  Medication                                                                                                                                                      
   Warfarin                    2 (0.1)                6 (0.2)                0.018\*      0.892        2 (0.1)                4 (0.3)                0.668\*      0.414
   GPI                         222 (16.2)             604 (16.4)             0.033\*      0.857        202 (15.6)             233 (18.0)             2.654\*      0.103

Data are presented as *n* (%), mean ± SD or median (interquartile range). \**χ*^2^ values; ^†^*t* values; ^‡^*z* value. PPI: Proton-pump inhibitors; mTEG: Modified thromboelastograph; PSM: Propensity score matching; PAD: Peripheral artery disease; CVD: Cerebrovascular disease; MI: Myocardial infarction; PCI: Percutaneous coronary intervention; CABG: Coronary artery bypass grafting; LVEF: Left ventricular ejection fraction; SAP: Systolic blood pressure; BNP: Brain natriuretic peptide; eGFR: Estimated glomerular filtration rate; ESR: Erythrocyte sedimentation rate; IABP: Intra-aortic balloon pump; GPI: Glycoprotein IIb/IIIa inhibitors; SD: Standard deviation; 1 mmHg=0.133 kPa.

Before PSM, the ADP-induced platelet aggregation inhibition was lower in PPI users than in non-PPI users (42.0 ± 30.9% vs. 46.4 ± 31.4%, *t* = 4.435, *P* \< 0.001). A greater proportion of patients had CLR in the group that received PPIs (41.3% vs. 36.1%, χ^2^ = 11.420, *P* = 0.001). After PSM, the differences were even larger, and 30 (2.3%) non-PPI users were identified as having a CLR, whereas 528 (40.7%) PPI users were identified as having a CLR (2.3% vs. 40.7%, χ^2^ = 566.262, *P* \< 0.001) \[[Table 3](#T3){ref-type="table"}\].

###### 

Platelet function results among patients receiving mTEG according to PPI use before and after PSM

  Variables              Before PSM          After PSM                                                                                     
  ---------------------- ------------------- ------------------- ----------- --------- ------------------- ------------------- ----------- ---------
  ADP-inhibition (%)     37.6 (15.9--64.2)   42.2 (20.4--73.2)   −4.402^†^   \<0.001   37.7 (16.1--64.9)   43.0 (23.0--75.0)   −4.750^†^   \<0.001
  ADP-inhibition \<30%   565 (41.3)          1327 (36.1)         11.420\*    0.001     528 (40.7)          30 (2.3)            566.261\*   \<0.001

Data are presented as *n* (%) or median (interquartile range). \**χ*^2^ values; ^†^*z* values. mTEG: Modified thromboelastograph; PSM: Propensity score matching; PPI: Proton-pump inhibitors; ADP: Adenosine diphosphate.

Clinical outcomes {#sec2-9}
-----------------

Before PSM, the occurrence of MACCE between PPI users and non-PPI users in the total population showed no significant difference (12.7% vs. 12.5%, χ^2^ = 0.086, *P* = 0.769), and no differences were observed in the incidence of all-cause death (1.4% vs. 1.3%, χ^2^ = 0.097, *P* = 0.755), MI (2.4% vs. 2.0%, χ^2^ = 0.950, *P* = 0.330), unplanned TVR (9.1% vs. 8.8%, χ^2^ = 0.199, *P* = 0.655), ST (1.2% vs. 0.9%, χ^2^ = 1.095, *P* = 0.295), stroke (1.4% vs. 1.4%, χ^2^ = 0.084, *P* = 0.772), bleeding (6.6% vs. 6.5%, χ^2^ = 0.060, *P* = 0.806), BARC 3 or 5 bleeding (0.5% vs. 0.5%, χ^2^ = 0.095, *P* = 0.758), and gastrointestinal bleeding events (1.7% vs. 1.2%, χ^2^ = 2.272, *P* = 0.132). After PSM, the occurrence of MACCE (12.4% vs. 12.7%, χ^2^ = 0.048, *P* = 0.827), all-cause death (1.3% vs. 1.4%, χ^2^ = 0.080, *P* = 0.777), MI (2.4% vs. 2.4%, χ^2^ = 0.000, *P* = 0.998), unplanned TVR (8.9% vs. 9.0%, χ^2^ = 0.006, *P* = 0.937), ST (1.1% vs. 0.9%, χ^2^ = 0.425 *P* = 0.515), stroke (1.4% vs. 1.1%, χ^2^ = 0.721, *P* = 0.396), bleeding (7.0% vs. 5.9%, χ^2^ = 1.860, *P* = 0.173), and BARC 3 or 5 bleeding events (0.5% vs. 0.2%, χ^2^ = 2.623, *P* = 0.105) did not significantly differ between the two groups, and there was only a trend for an increase in gastrointestinal bleeding events in PPI users (1.8% vs. 1.2%, χ^2^ = 2.960, *P* = 0.085) \[[Table 4a](#T4){ref-type="table"}\].

###### 

Clinical outcomes among all patients according to PPI use before and after PSM

  Clinical endpoint    Before PSM   After PSM                                                        
  -------------------- ------------ ------------ ------- ------- ------------ ------------ --------- -------
  Primary endpoint                                                                                   
   MACCE               273 (12.7)   716 (12.5)   0.086   0.769   244 (12.4)   249 (12.7)   0.048     0.827
  Secondary endpoint                                                                                 
   All cause death     30 (1.4)     75 (1.3)     0.097   0.755   25 (1.3)     27 (1.4)     0.080     0.777
   MI                  51 (2.4)     116 (2.0)    0.950   0.330   48 (2.4)     48 (2.4)     \<0.001   0.998
   Unplanned TVR       195 (9.1)    504 (8.8)    0.199   0.655   174 (8.9)    176 (9.0)    0.006     0.937
   Stent thrombosis    25 (1.2)     52 (0.9)     1.095   0.295   21 (1.1)     17 (0.9)     0.425     0.515
   Stroke              31 (1.4)     78 (1.4)     0.084   0.772   28 (1.4)     22 (1.1)     0.721     0.396
  Safety endpoint                                                                                    
   Bleeding            142 (6.6)    372 (6.5)    0.060   0.806   137 (7.0)    116 (5.9)    1.860     0.173
   BARC 3 or 5         10 (0.5)     10 (0.5)     0.095   0.758   10 (0.5)     4 (0.2)      2.623     0.105
   GI bleeding         36 (1.7)     71 (1.2)     2.272   0.132   36 (1.8)     23 (1.2)     2.960     0.085

Data are presented as *n* (%). PPI: Proton-pump inhibitors; PSM: Propensity score matching; MACCE: Major adverse cardiovascular and cerebrovascular events; MI: Myocardial infarction; TVR: Target vessel revascularization; BARC: Bleeding Academic Research Consortium; GI: Gastrointestinal.

After multivariate Cox proportional hazards regression analysis, there was only a trend for an increase in BARC 3 or 5 bleeding and gastrointestinal bleeding in PPI users after PSM (*HR*: 0.586, 95% *CI*: 0.341--1.009, *P* = 0.054), and the other endpoints showed no significant differences after multivariate adjustment, regardless of PSM, between two groups \[[Table 4b](#T5){ref-type="table"}\].

###### 

Multivariate Cox proportional regression analysis among all patients according to PPI use before and after PSM

  Clinical endpoint    Before PSM             After PSM                          
  -------------------- ---------------------- ----------- ---------------------- -------
  Primary endpoint                                                               
   MACCE               1.049 (0.854--1.289)   0.651       0.970 (0.808--1.165)   0.745
  Secondary endpoint                                                             
   All cause death     0.775 (0.410--1.465)   0.433       0.935 (0.534--1.634)   0.812
   MI                  0.838 (0.508--1.383)   0.490       0.904 (0.597--1.368)   0.634
   Unplanned TVR       1.042 (0.822--1.322)   0.733       0.992 (0.798--1.233)   0.942
   Stent thrombosis    0.964 (0.451--2.064)   0.925       0.736 (0.380--1.425)   0.363
   Stroke              2.171 (0.896--5.258)   0.086       0.730 (0.409--1.302)   0.286
  Safety endpoint                                                                
   Bleeding            1.094 (0.821--1.458)   0.539       0.841 (0.651--1.086)   0.184
   BARC 3 or 5         0.572 (0.218--1.502)   0.257       0.341 (0.103--1.132)   0.079
   GI bleeding         0.800 (0.455--1.409)   0.440       0.586 (0.341--1.009)   0.054

PPI: Proton-pump inhibitors; PSM: Propensity score matching; *HR*s: Hazard ratios; *CI*s: Confidence intervals; MACCE: Major adverse cardiovascular and cerebrovascular events; MI: Myocardial infarction; TVR: Target vessel revascularization; BARC: Bleeding Academic Research Consortium; GI: Gastrointestinal.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

In this prospective observational study, we investigated the impact of concomitant administration of PPIs with DAPT therapy among patients who underwent PCI. The major strength of this study was the use of a large sample size from a single-center database with a long follow-up duration of 2 years, and we evaluated the interaction between DAPT and PPIs in both pharmacodynamic and clinical aspects. To overcome this selection bias for PPI use, PSM was implemented so that the 2 cohorts could be meaningfully compared. The study has the following notable findings.

First, approximately 27.2% of the patients were prescribed PPIs; these patients were likely to be older and female and to have increased comorbid illness, such as diabetes mellitus or cerebral vascular disease, and they were more likely to present with lower hemoglobin, lower creatinine clearance, and higher BNP. The PPI use pattern suggests that physicians were prescribing PPIs to those who were at higher baseline bleeding risk in accordance with new recommendations.\[[@ref11]\] Interestingly, patients with prior MI were less likely to be prescribed PPIs, possibly due to concerns regarding the interaction between PPI and clopidogrel.

Second, the inhibition of platelet aggregation assessed by mTEG was significantly lower in patents with concomitant PPI use than in those without. In addition, a significant association between CLR and treatment with PPIs was observed. In 2006, Gilard *et al*.\[[@ref4][@ref17]\] first reported the competitive effect of PPIs on CYP2C19 by means of a platelet phosphorylated vasodilator-stimulated phosphoprotein test, which might diminish the antiplatelet action of clopidogrel. While vasodilator-stimulated phosphoprotein phosphorylation evaluates the platelet activation from the P2Y12 ADP receptor, mTEG uses whole blood to evaluate the clot strength and ensures a quantitative analysis of platelet function, which is more likely to mirror the platelet behavior in human blood vessels and is capable of identifying patients undergoing PCI who are at risk for ischemic events.\[[@ref18][@ref19]\]

Third, the combination of PPIs with DAPT might not increase the risk of MACCE at up to 2 years of follow-up. This finding is consistent with those of randomized controlled trials, which suggested no association of PPI use with increased risk of ischemic events.\[[@ref20][@ref21][@ref22]\] Some retrospective analyses suggested higher incidence rates of cardiovascular events in patients taking both DAPT and PPIs.\[[@ref5][@ref6][@ref7]\] The reason might be a lack of adjustment for confounding factors. A meta-analysis that included a total of 23 studies and 222,311 patients showing increased cardiovascular risks with PPIs in the absence of clopidogrel also suggested that confounding and bias were strong possibilities.\[[@ref21]\] The PLATO trial studied 9291 patients with concomitant clopidogrel use and found that the risk of 1-year cardiovascular events was higher (*HR* 1.20, 95% *CI* 1.04--1.38) in patients treated with PPIs than in patients who were not treated with PPI. Similarly, this increased risk in the PPI group was also reported with the use of ticagrelor, which is a P2Y12 inhibitor that does not need biotransformation and has no effect on the CYP2C19 isoenzyme. That study also indicated that PPI use is more of a marker for higher rates of cardiovascular events.\[[@ref22]\]

There are several limitations of this study. The use of PPIs was not selected in a randomized fashion and was determined at the discretion of the physician. The indication for PPI treatment was not captured. Although PSM was performed, potential unmeasured confounding factors remain. Different PPI types might have variable interactions with the cytochrome P450 system, which is not specified in this study. In this observational study, we did not conduct a before and after analysis, which could provide more powerful evidence on the pharmacodynamic effect of PPIs on platelet aggregation inhibition by clopidogrel. In addition, PPI use might be discontinued during the 2-year follow-up.

In conclusion, the combination of PPIs with DAPT was not associated with increased risk of MACCE in patients who underwent PCI at up to 2 years of follow-up.
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